Clinical Trial Update: Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a monoclonal antibody therapy in combination with sargramostim and interleukin-2 in children with neuroblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• monoclonal antibody therapy targeting GD2 (anti-GD2 monoclonal antibody)
• sargramostim (sargramostim)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Disseminated Neuroblastoma, Recurrent Neuroblastoma | Phase 1 | Status: COMPLETED